Pharmaceuticals

Respiratory Biologics Market Forecast 2026–2035: Data Trends and Industry Insights

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the respiratory biologics market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Respiratory Biologics Market in 2030?

The respiratory biologics market has recently seen significant expansion in its size. It is forecast to grow from $7.41 billion in 2025 to $8.61 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.3%. The historical development of this market is linked to factors such as limitations of conventional inhalers, an increase in severe asthma cases, the authorization of biologic therapies, advancements in immunology research, and the expansion of specialty clinics.

The size of the respiratory biologics market is anticipated to experience significant expansion over the upcoming years. This market is projected to reach $15.66 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.1%. Contributing factors to this growth throughout the forecast period include the advancement of precision respiratory medicine, the broadening of biologics pipelines, increased healthcare spending, enhanced reimbursement policies, and existing unmet needs within severe respiratory diseases. Key trends foreseen for the forecast period encompass a growing uptake of targeted biologic therapies, an increase in severe asthma treatments, the evolution of biomarker-based patient selection, a rise in the application of injectable respiratory drugs, and a move towards long-acting biologic agents.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

What Drivers Are Influencing Production Trends In The Respiratory Biologics Market?

The increase in air pollution is anticipated to stimulate the expansion of the respiratory biologics market moving forward. Air pollution describes the existence of harmful substances such as gases, particulate matter, and biological molecules within the Earth’s atmosphere, which can adversely affect human health and the environment. This pollution is intensifying due to rising industrialization and urbanization, leading to greater emissions of pollutants from factories, vehicles, and construction activities. Respiratory biologics aid in counteracting the health consequences of air pollution by offering targeted therapies that diminish inflammation and improve lung function in individuals exposed to airborne pollutants. For example, in January 2025, the Environmental Protection Agency, a US-based government agency, stated that the United States released over 66 million tons of pollutants into the atmosphere in 2023. Thus, the escalating air pollution is propelling the growth of the respiratory biologics market.

Which Segments Are Gaining Traction In The Respiratory Biologics Market?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegments:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Chronic Rhinosinasitis: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

Which Trends Are Guiding The Evolution Of The Respiratory Biologics Market?

Leading companies within the respiratory biologics market are prioritizing the development of innovative biologic treatments, such as targeted immune therapies for chronic respiratory conditions, with the aim of delivering specific interventions to reduce inflammation and improve lung function. Targeted immune therapies for chronic respiratory diseases are treatments designed to help regulate the body’s immune system to decrease swelling and alleviate breathing issues in long-term lung ailments. For instance, in September 2024, Sanofi S.A., a France-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Dupixent (dupilumab) for use as an add-on maintenance therapy for adults with chronic obstructive pulmonary disease (COPD) that was inadequately controlled and presented with an eosinophilic phenotype. This approval marked a significant achievement, as Dupixent became the first biologic medicine authorized in the US for treating this specific demographic of COPD patients.

Who Are The Core Companies Influencing Trends In The Respiratory Biologics Market?

Major companies operating in the respiratory biologics market are Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Amgen Inc., Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Glenmark Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

Which Regions Are Projected To Dominate The Respiratory Biologics Market In The Coming Years?

North America was the largest region in the respiratory biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Respiratory Biologics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

Browse Through More Reports Similar to the Global Respiratory Biologics Market 2026, By The Business Research Company

Respiratory Devices And Equipment Therapeutic And Diagnostic Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

Respiratory Devices And Equipment Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Disease Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795